Advances in clinical fibrinolysis.
The discovery of a fast-acting plasminogen activator inhibitor has resulted in the notion that the balance between tissue-type plasminogen activator and its inhibitor determines the net fibrinolytic activity of blood. The inhibitor shows a rapidly fluctuating acute-phase pattern, which may be important in relation to thrombosis in acute disease. Other newly discovered modulators of the fibrinolytic system include histidine-rich glycoprotein, tetranectin and thrombospondin. The role of fibrin as a cofactor in its own dissolution is further elucidated with emphasis on local aspects. Therapeutic inhibition of overactive fibrinolysis by various drugs needs careful monitoring. Prophylactic stimulation of fibrinolysis is possible, e.g. by stanozolol or other drugs that lower inhibitor levels, but its proven value is as yet limited. Results of clinical trials with activators of the fibrinolytic system as thrombolytic agents are discussed in relation to the physiology of the fibrinolytic system.
D003327:Coronary Disease / Q000188:drug therapy; D005174:Factor XII / Q000502:physiology; D005337:Fibrin / Q000502:physiology; D005340:Fibrinogen / Q000502:physiology; D005341:Fibrinolysin / Q000502:physiology; D005342:Fibrinolysis; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006023:Glycoproteins / Q000502:physiology; D006801:Humans; D010958:Plasminogen / Q000502:physiology; D010960:Plasminogen Activators / Q000502:physiology / Q000627:therapeutic use; D015849:Plasminogen Inactivators; D010959:Tissue Plasminogen Activator / Q000502:physiology / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D006023:Glycoproteins; D015849:Plasminogen Inactivators; D005174:Factor XII; D005337:Fibrin; D005340:Fibrinogen; D010958:Plasminogen; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator; D005341:Fibrinolysin